Cutaneous manifestations of ANCA-associated vasculitis

Cutaneous manifestations of ANCA-associated vasculitis

Bibliografske podrobnosti
Main Authors:	Chiesafuxench, Z, Micheletti, R, Luqmani, R, Watts, R, Craven, A, Merkel, P
Format:	Conference item
Izdano:	Wiley 2016

Podobne knjige/članki

Cutaneous manifestations of ANCA-associated vasculitis are common, varied, and associated with systemic disease
od: Micheletti, R, et al.
Izdano: (2017)

Global ethnic and geographic idfferences in the clinical features of ANCA-associated vasculitis
od: Pearce, F, et al.
Izdano: (2016)

Predictors of renal involvement in ANCA associated vasculitis
od: Kronbichler, A, et al.
Izdano: (2018)

Association between age at diagnosis and clinical presentation and outcomes of anca-associated vasculitis. analysis from the dcvas study
od: Monti, S, et al.
Izdano: (2018)

Damage assessment in ANCA-associated vasculitis.
od: Bhamra, K, et al.
Izdano: (2012)

Maintenance of clinical remission in ANCA-associated vasculitis.
od: Luqmani, R
Izdano: (2013)

Outcome measures in ANCA-associated vasculitis.
od: Suppiah, R, et al.
Izdano: (2010)

Opinion: Maintenance of clinical remission in ANCA-associated vasculitis
od: Luqmani, R
Izdano: (2013)

Diagnosis and management of ANCA associated vasculitis.
od: Berden, A, et al.
Izdano: (2012)

Cardiovascular outcomes in ANCA associated vasculitis
od: Mukhtyar, C, et al.
Izdano: (2008)

ANCA-associated vasculitis: Where can we go from here?
od: Luqmani, R
Izdano: (2010)

Treatment of renal manifestations of ANCA-associated vasculitis
od: Kresimir Galesic, et al.
Izdano: (2013-01-01)

Comparison of disease activity measures for ANCA-associated vasculitis.
od: Merkel, P, et al.
Izdano: (2004)

Classification criteria for the anca-associated vasculitides
od: Robson, J, et al.
Izdano: (2019)

Does a gating policy for ANCA overlook patients with ANCA associated vasculitis? An audit of 263 patients.
od: Arnold, D, et al.
Izdano: (2010)

ANCA Associated Vasculitis Subtypes: Response [Letter]
od: Merkel PA, et al.
Izdano: (2022-09-01)

The UK & Ireland Vasculitis Registry (UKIVAS): Cross-sectional data on the first 2290 Patients with anti-neutrophil cytoplasm (ANCA) associated vasculitis (AAV)
od: Luqmani, R, et al.
Izdano: (2017)

EULAR/ERA-EDTA RECOMMENDATIONS FOR THE MANAGEMENT OF ANCA-ASSOCIATED VASCULITIS
od: Yates, M, et al.
Izdano: (2016)

Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody-associated vasculitis
od: Pearce, F, et al.
Izdano: (2017)

BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.
od: Lapraik, C, et al.
Izdano: (2007)

The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis.
od: Merkel, P, et al.
Izdano: (2011)

THE PROGNOSTIC VALUE OF THE BIRMINGHAM VASCULITIS ACTIVITY SCORE AND THE VASCULITIS DAMAGE INDEX IN ANCA-ASSOCIATED VASCULITIS
od: Suppiah, R, et al.
Izdano: (2011)

BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis.
od: Ntatsaki, E, et al.
Izdano: (2014)

Explaining fatigue in ANCA-associated vasculitis.
od: Basu, N, et al.
Izdano: (2013)

Explaining fatigue in ANCA-associated vasculitis
od: Basu, N, et al.
Izdano: (2013)

Long-term survival of ANCA-associated vasculitis
od: Flossmann, O, et al.
Izdano: (2009)

DEVELOPMENT OF DIAGNOSTIC CRITERIA FOR PRIMARY ANCA-ASSOCIATED SYSTEMIC VASCULITIS (AASV)
od: McLaren, J, et al.
Izdano: (2003)

Case report: Testicular manifestation of ANCA vasculitis
od: Noah J. Sandel, et al.
Izdano: (2025-03-01)

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials.
od: Suppiah, R, et al.
Izdano: (2011)

Blue toe syndrome as the initial manifestation of ANCA-associated vasculitis
od: Marinchev Liubomir, et al.
Izdano: (2013-10-01)

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials
od: Suppiah, R, et al.
Izdano: (2011)

Markers for work disability in ANCA-associated vasculitis
od: Basu, N, et al.
Izdano: (2013)

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
od: Yates, M, et al.
Izdano: (2016)

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
od: Jones, R, et al.
Izdano: (2010)

OP0053 Eular/ERA-EDTA Recommendations for The Management of Anca-Associated Vasculitis
od: Yates, M, et al.
Izdano: (2016)

Efficacy and safety of belimumab and azathioprine for maintenance of remission in ANCA-associated vasculitis: a randomized controlled study
od: Jayne, D, et al.
Izdano: (2019)

Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.
od: Merkel, P, et al.
Izdano: (2009)

Long-term patient survival in ANCA-associated vasculitis
od: Flossmann, O, et al.
Izdano: (2011)

Long-term patient survival in ANCA-associated vasculitis.
od: Flossmann, O, et al.
Izdano: (2011)

EULAR recommendations for conducting clinical studies and/or clinical trials in ANCA-associated vasculitis
od: Luqmani, R, et al.
Izdano: (2007)